atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial of RL-007 in Cognitive Impairment Associated with Schizophrenia

Written By ATAI

atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced positive topline data from its Phase 2a study of RL-007 for Cognitive Impairment Associated with Schizophrenia (CIAS).

Read more

ATAI
Previous

KOL R&D Day - Cognitive Impairment Associated with Schizophrenia (CIAS)
Next

Recognify Life Sciences to Commence Phase 2a Study in Cognitive Impairment Associated with Schizophrenia